Skip to main content
Signal8

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

$DWTXPress releaseMay 7, 2026, 8:30 AM ETRead the release

Dogwood Therapeutics announced it will report its first quarter 2026 financial results before the market open on Thursday, May 14, 2026. The company's pipeline includes two first-in-class candidates, Halneuron and SP16 IV, with Halneuron currently in Phase 2b development for chemotherapy-induced neuropathic pain. CK Life Sciences Int’l., (Holdings) Inc.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.